Blood Proteome Profiling Identifies Biomarkers in Ischemic Stroke
China80 participantsStarted 2024-12-01
Plain-language summary
Endovascular thrombectomy and intravenous thrombolysis have become key therapeutic approaches for acute ischemic stroke. However, due to time window limitations, many patients are unable to receive reperfusion therapy, and the majority only receive supportive treatment. Ischemic stroke-related complications, including edema and infection, gradually subside after 7 days post-stroke, with the patient's condition generally stabilizing. Endogenous repair mechanisms will play a critical role in the coming months. This study aims to predict prognostic biomarkers for ischemic stroke patients who have not undergone reperfusion therapy, using blood proteomics data. All samples in our study are derived from this experiment. Our goal is to elucidate the molecular mechanisms underlying post-reperfusion prognosis and to provide insights for optimizing stroke treatment strategies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18.
* Clinical signs consistent with acute ischemic stroke (TOAST classification: large artery atherosclerosis)
* 7 to 30 days from symptom onset.
Exclusion Criteria:
* Severe infection or multiple organ failure.
* Untreated moderate or severe coronary artery stenosis, or a history of coronary artery bypass surgery.
* Ongoing hemodialysis or peritoneal dialysis, or severe renal insufficiency characterized by a glomerular filtration rate (GFR) of less than 30 ml/min or serum creatinine levels exceeding 220 mmol/L (2.5 mg/dl).
* Known intracranial aneurysm or cerebral arteriovenous malformation.
* Malignant brain tumor or central nervous system (CNS) infection.
* Pre-existing neurological or psychiatric conditions that could confound the neurological or functional assessments.
* Baseline platelet count \<50 × 109/L.
* Pregnancy or lactation at the time of admission.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This stroke biomarker study has already been completed — could you tell me what findings or data came out of it, and whether any of the blood protein markers they identified might be relevant to my own situation?
2Since this study was focused on profiling blood proteins to find biomarkers rather than testing a treatment, how could results from research like this actually affect the care decisions we make for me going forward?
3Were the blood samples in this study collected from people with strokes similar to mine in type or severity, and does that affect how meaningful any findings might be for my case?
4If new biomarkers were identified through this kind of research, what would the next steps typically look like before those markers could be used in routine clinical care or to guide my treatment?
5Are there any current or upcoming studies building on this biomarker research that you think would be worth me looking into, given my specific stroke history?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.